Metabolic mapping of gliomas using hybrid MR-PET imaging: Feasibility of the method and spatial distribution of metabolic changes

Investigative Radiology

Volumn 48, Issue 5, 2013, Pages 295-301

  Bisdas, Sotirios ^a   Ritz, Rainer ^a   Bender, Benjamin ^a   Braun, Christian ^a   Pfannenberg, Christina ^a   Reimold, Matthias ^a   Naegele, Thomas ^a   Ernemann, Ulrike ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

gliomas; methionine; MR; PET; spectroscopy

Indexed keywords

AMINO ACID; CHOLINE; CREATININE; METHIONINE; N ACETYLASPARTIC ACID;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CELL POPULATION; CELL PROLIFERATION; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GLIOMA; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MEMBRANE TRANSPORT; METABOLIC ACTIVATION; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SAMPLING; TUMOR CELL; WORLD HEALTH ORGANIZATION;

ADULT; AGED; BRAIN; BRAIN NEOPLASMS; FEASIBILITY STUDIES; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METHIONINE; MIDDLE AGED; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84876296070     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31827188d6     Document Type: Article

References (49)

1. Kleihues P, Burger PC, Scheithauer BW, et al. Histological Typing of Tumours of the Central Nervous System. Berlin, Germany: Springer-Verlag; 1993:112 xii.
2. Schiff D, Brown PD, Giannini C. Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology. 2007;69:1366-1373.
3. Leighton C, Fisher B, Bauman G, et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol. 1997;15:1294-1301.
4. Mittler MA, Walters BC, Stopa EG. Observer reliability in histological grading of astrocytoma stereotactic biopsies. J Neurosurg. 1996;85:1091-1094.
5. Scott JN, Brasher PM, Sevick RJ, et al. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology. 2002; 59:947-949.
6. Kim S, Chung JK, Im SH, et al. 11C-methionine PETas a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2005;32:52-59.
7. Langen KJ, Tatsch K, Grosu AL, et al. Diagnostics of cerebral gliomas with radiolabeled amino acids. Dtsch Arztebl Int. 2008;105:55-61.
8. Kato T, Shinoda J, Nakayama N, et al. Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positronemission tomography. AJNR Am J Neuroradiol. 2008;29:1176-1182.
9. Stadlbauer A, Gruber S, Nimsky C, et al. Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spec-troscopic imaging. Radiology. 2006;238:958-969.
10. Herminghaus S, Pilatus U, Moller-Hartmann W, et al. Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed. 2002;15:385-392.
11. Hattingen E, Raab P, Franz K, et al. Prognostic value of choline and creatine in WHO grade II gliomas. Neuroradiology. 2008;50:759-767.
12. Luyten PR, Marien AJ, Heindel W, et al. Metabolic imaging of patients with intracranial tumors: H-1 MR spectroscopic imaging and PET. Radiology. 1990;176:791-799.
13. Stadlbauer A, Prante O, Nimsky C, et al. Metabolic imaging of cerebral glio-mas: spatial correlation of changes in O-(2-18F-fluoroethyl)-L-tyrosine PET and proton magnetic resonance spectroscopic imaging. J Nucl Med. 2008;49:721-729.
14. Kwee SA, Coel MN, Lim J, et al. Combined use of F-18 fluorocholine positron emission tomography and magnetic resonance spectroscopy for brain tumor evaluation. J Neuroimaging. 2004;14:285-289.
15. Floeth FW, Pauleit D, Wittsack HJ, et al. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg. 2005;102: 318-327.
16. Miwa K, Shinoda J, Yano H, et al. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry. 2004;75:1457-1462.
17. Ledezma CJ, Chen W, Sai V, et al. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol. 2009;71: 242-248.
18. Boss A, Kolb A, Hofmann M, et al. Diffusion tensor imaging in a human PET/MR hybrid system. Invest Radiol. 2010;45:270-274.
19. Schlemmer HP, Pichler BJ, Schmand M, et al. Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology. 2008;248:1028-1035.
20. Hofmann M, Steinke F, Scheel V, et al. MRI-based attenuation correction for PET/MRI: a novel approach combining pattern recognition and atlas registration. J Nucl Med. 2008;49:1875-1883.
21. Ceyssens S, Van Laere K, de Groot T, et al. [11C]methionine PET, histo-pathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol. 2006;27:1432-1437.
22. Matsumura A, Isobe T, Anno I, et al. Correlation between choline and MIB-1 index in human gliomas: a quantitative in proton MR spectroscopy study. J Clin Neurosci 2005;12:416-420.
23. Di Costanzo A, Scarabino T, Trojsi F, et al. Multiparametric 3T MR approach to the assessment of cerebral gliomas: tumor extent and malignancy. Neuror-adiology. 2006;48:622-631.
24. Catana C, Procissi D, Wu Y, et al. Simultaneous in vivo positron emission tomography and magnetic resonance imaging. Proc Natl Acad Sci U S A. 2008; 105:3705-3710.
25. Boss A, Bisdas S, Kolb A, et al. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med. 2010;51:1198-1205.
26. Pirotte B, Goldman S, Massager N, et al. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg. 2004;101:476-483.
27. Stober B, Tanase U, Herz M, et al. Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells. Eur J Nucl Med Mol Imaging. 2006;33:932-939.
28. Bustany P, Chatel M, Derlon JM, et al. Brain tumor protein synthesis and histological grades: a study by positron emission tomography (PET) with C11-L-methionine. J Neurooncol. 1986;3:397-404.
29. Herholz K, Holzer T, Bauer B, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316-1322.
30. Kato T, Shinoda J, Oka N, et al. Analysis of 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity. AJNR Am J Neuroradiol. 2008;29:1867-1871.
31. De Witte O, Goldberg I, Wikler D, et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg. 2001;95:746-750.
32. Bergstrom M, Ericson K, Hagenfeldt L, et al. PET study of methionine accumulation in glioma and normal brain tissue: competition with branched chain amino acids. J Comput Assist Tomogr. 1987;11:208-213.
33. Moulin-Romsee G, D'Hondt E, de Groot T, et al. Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine? Eur J Nucl Med Mol Imaging. 2007;34:2082-2087.
34. Utriainen M, Komu M, Vuorinen V, et al. Evaluation of brain tumor metabolism with [11C]choline PET and 1H-MRS. J Neurooncol. 2003;62:329-338.
35. Fulham MJ, Bizzi A, Dietz MJ, et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology. 1992; 185:675-686.
36. Pirzkall A, Nelson SJ, McKnight TR, et al. Metabolic imaging of low-grade gliomas with three-dimensional magnetic resonance spectroscopy. Int J Radiat Oncol Biol Phys. 2002;53:1254-1264.
37. Li X, Lu Y, Pirzkall A, et al. Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients. J Magn Reson Imaging. 2002;16:229-237.
38. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003;24:1989-1998.
39. Kinoshita Y, Yokota A. Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy. NMR Biomed. 1997;10:2-12.
40. Galanaud D, Chinot O, Nicoli F, et al. Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. J Neurosurg. 2003;98:269-276.
41. Goldman S, Levivier M, Pirotte B, et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med. 1997;38:1459-1462.
42. Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432-445.
43. Bhakoo KK, Williams SR, Florian CL, et al. Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res. 1996;56:4630-4635.
44. Usenius JP, Vainio P, Hernesniemi J, et al. Choline-containing compounds in human astrocytomas studied by 1H NMR spectroscopy in vivo and in vitro. J Neurochem. 1994;63:1538-1543.
45. Hlaihel C, Guilloton L, Guyotat J, et al. Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas. J Neurooncol. 2010;97:73-80.
46. Alimenti A, Delavelle J, Lazeyras F, et al. Monovoxel 1H magnetic resonance spectroscopy in the progression of gliomas. Eur Neurol. 2007;58:198-209.
47. Tedeschi G, Lundbom N, Raman R, et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg. 1997;87:516-524.
48. Smits A, Baumert BG. The Clinical Value of PETwith Amino Acid Tracers for Gliomas WHO Grade II. Int J Mol Imaging. 2011;2011:372509.
49. Kracht LW, Friese M, Herholz K, et al. Methyl-[11C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging. 2003;30:868-873.